Visual Field Tests
Conditions
Keywords
Humphrey visual fields, methylphenidate, attention deficit disorder, MoCa questionnaire
Brief summary
Study will include adults with abnormal visual fields. Half of them will be given either methylphenidate 10mg 2 hours before repeating the visual field test. the rest will serve as controls. All Subjects will also have a complete eye examination, a short questionnaire and a questionnaire to screen for attention deficit disorder. The investigators will compare the visual field results between the 2 tests.
Detailed description
Healthy adults with abnormal visual fields will be offered to participate Subjects will have a complete ophthalmic examination including dilated fundus examination. Subjects with clear explanation for a visual field defect (e.g. optic neuropathy or retinal disorder) will be excluded from the study the subjects will be randomly assigned to the study group and control group using a 1:1 allocation. Subjects in the study group will be provided with a single tablet of methylphenidate 10 mg to be taken orally 2 hours before repeating their visual field test. The control group will not receive any placebo Both groups will repeat their visual fields. Both groups will fill out a short questionnaire to evaluate their experience in the second visual field test. The study group will also fill out a screening questionnaire to rule out previously undiagnosed attention deficit disorder. Two experienced ophthalmologists will separately interpret the visual fields results and compare the first and second visual fields of each subject, while being blinded to which group he was in. Subjects will be provided with their test results and the ophthalmologist interpretation.
Interventions
DRUGmethylphenidate
a single dose of methylphenidate 10 mg to be taken orally in the morning
OTHERguidance
subjects will be given an explanation and advice about how to perform well in visual field testing
Sponsors
Rabin Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
* abnormal visual fields * must be able to swallow pills
Exclusion criteria
* psychiatric disorder * dementia * ocular disorder which is known to cause abnormal visual fields * prescription of psychoactive medications * visual acuity lower than 20/100 * cardiac arrhythmia * hypersensitivity to methylphenidate * prescription of warfarin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| improvement rate of a repeat visual field result | immediate | the percentage of subjects whose second (repeat) visual field has improved compared to the first visual field - as interpreted by independent blinded ophthalmologists |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Humphrey visual field Mean Deviation (MD) | immediate | the MD of the Humphrey visual field in the study and control groups will be compared |
| Humphrey visual field severity score | immediate | based on the Humphrey visual field gray scale each visual field will be given a score between 1 and 4. 1 = normal 2=enlargement of the blind spot 3=either a nasal or temporal visual field 4= diffuse visual field loss |
Countries
Israel
Outcome results
None listed